Proactively evaluate Alcon Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
|Event Date||Event Type||Company Name||Ticker Symbol||Drug Name||Therapy Area||Indication||Source Type|
|01 Nov 2021||GDCTXXXX||Lorem||Lorem||Lorem||XXXX||Planned||Lorem|
|30 Oct 2021||Phase II Trial Completion||Alcon Inc; University of Alabama at Birmingham||ALC||naphazoline||Ophthalmology||Keratoconjunctivitis Sicca (Dry Eye)||Clinical Trial Registry|
|31 Aug 2021||Phase II Trial Initiation||Alcon Inc; University of Alabama at Birmingham||ALC||naphazoline||Ophthalmology||Keratoconjunctivitis Sicca (Dry Eye)||Clinical Trial Registry|
|01 Jun 2021||Phase II Trial Initiation||Alcon Inc||ALC||FID-123238; Systane hydration||Ophthalmology||Keratoconjunctivitis Sicca (Dry Eye)||Clinical Trial Registry|
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer